Risk of misclassification with a non-fasting lipid profile in secondary cardiovascular prevention

被引:3
作者
Klop, Boudewijn [1 ]
Hartong, Simone C. C. [2 ]
Vermeer, Henricus J. [3 ,4 ]
Schoofs, Mariette W. C. J. [2 ]
Kofflard, Marcel J. M. [1 ]
机构
[1] Albert Schweitzer Hosp, Dept Cardiol, POB 444, NL-3300 AK Dordrecht, Netherlands
[2] Albert Schweitzer Hosp, Dept Internal Med, Dordrecht, Netherlands
[3] Result Lab, Dordrecht, Netherlands
[4] Albert Schweitzer Hosp, Dept Clin Chem, Dordrecht, Netherlands
关键词
Non-fasting; LDL-C; Non-HDL-C; Apolipoprotein B; Misclassification; Treatment target; LDL CHOLESTEROL; REDUCING LIPIDS; APOLIPOPROTEINS; LIPOPROTEINS; VARIABILITY; DYSLIPIDEMIA; GUIDELINES; EFFICACY; SOCIETY; SAFETY;
D O I
10.1016/j.cca.2017.07.005
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Aims: Routinely fasting is not necessary for measuring the lipid profile according to the latest European consensus. However, LDL-C tends to be lower in the non-fasting state with risk of misclassification. The extent of misclassification in secondary cardiovascular prevention with a non-fasting lipid profile was investigated. Methods and results: 329 patients on lipid lowering therapy for secondary cardiovascular prevention measured a fasting and non-fasting lipid profile. Cut-off values for LDL-C, non-HDL-C and apolipoprotein B were set at < 1.8 mmo1/1, < 2.6 mmo1/1 and < 0.8 g/l, respectively. Study outcomes were net misclassification with non fasting LDL-C (calculated using the Friedewald formula), direct LDL-C, non-HDL-C and apolipoprotein B. Net misclassification < 10% was considered clinically irrelevant. Mean age was 68.3 8.5 years and the majority were men (79%). Non-fasting measurements resulted in lower LDL-C (- 0.2 0.4 mmo1/1, P < 0.001), direct LDL-C (-0.1 0.2 mmo1/1, P = 0.001), non-HDL-C (- 0.1 0.4 mmol/l, P = 0.004) and apolipoprotein B (-0.02 0.10 g/1, P = 0.004). 36.0% of the patients reached a fasting LDL-C target of < 1.8 mmo1/1 with a significant net misclassification of 10.7% (95% CI 6.4-15.0%) in the non-fasting state. In the non-fasting state net misclassification with direct LDL-C was 5.7% (95% CI 2.1-9.2%), 4.0% (95% CI 1.0-7.4%) with non-HDL-C and 4.1% (95% CI 1.1-9.1%) with apolipoprotein B. Conclusion: Use of non-fasting LDL-C as treatment target in secondary cardiovascular prevention resulted in significant misclassification with subsequent risk of undertreatment, whereas non-fasting direct LDL-C, nonHDL-C and apolipoprotein B are reliable parameters.
引用
收藏
页码:90 / 95
页数:6
相关论文
共 24 条
[1]   2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult [J].
Anderson, Todd J. ;
Gregoire, Jean ;
Pearson, Glen J. ;
Barry, Arden R. ;
Couture, Patrick ;
Dawes, Martin ;
Francis, Gordon A. ;
Genest, Jacques ;
Grover, Steven ;
Gupta, Milan ;
Hegele, Robert A. ;
Lau, David C. ;
Leiter, Lawrence A. ;
Lonn, Eva ;
Mancini, G. B. John ;
McPherson, Ruth ;
Ngui, Daniel ;
Poirier, Paul ;
Sievenpiper, John L. ;
Stone, James A. ;
Thanassoulis, George ;
Ward, Richard .
CANADIAN JOURNAL OF CARDIOLOGY, 2016, 32 (11) :1263-1282
[2]   2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) [J].
Catapano, Alberico L. ;
Graham, Ian ;
De Backer, Guy ;
Wiklund, Olov ;
Chapman, M. John ;
Drexel, Heinz ;
Hoes, Arno W. ;
Jennings, Catriona S. ;
Landmesser, Ulf ;
Pedersen, Terje R. ;
Reiner, Zeljko ;
Riccardi, Gabriele ;
Taskinen, Marja-Riita ;
Tokgozoglu, Lale ;
Verschuren, W. M. Monique ;
Vlachopoulos, Charalambos ;
Wood, David A. ;
Luis Zamorano, Jose .
ATHEROSCLEROSIS, 2016, 253 :281-344
[3]   Does friedewald formula underestimate the risk of ischemic heart disease? [J].
Bansal E. ;
Kaur N. .
Indian Journal of Clinical Biochemistry, 2014, 29 (4) :496-500
[4]   How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic [J].
Barkas, Fotios ;
Milionis, Haralampos ;
Kostapanos, Michael S. ;
Mikhailidis, Dimitri P. ;
Elisaf, Moses ;
Liberopoulos, Evangelos .
CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (02) :221-228
[5]   Is it time to break the fast? - a paradigm shift in clinical lipidology [J].
Cabezas, Manuel Castro ;
Burggraaf, Benjamin ;
Klop, Boudewijn .
ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (21)
[6]   Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS) [J].
Chiang, Chern-En ;
Ferrieres, Jean ;
Gotcheva, Nina N. ;
Raal, Frederick J. ;
Shehab, Abdulla ;
Sung, Jidong ;
Henriksson, Karin M. ;
Hermans, Michel P. .
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2016, 23 (05) :567-587
[7]   The use of the non-fasting lipid profile for lipid-lowering therapy in clinical practice - Point of view [J].
de Vries, Marijke ;
Klop, Boudewijn ;
Cabezas, Manuel Castro .
ATHEROSCLEROSIS, 2014, 234 (02) :473-475
[8]   A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes [J].
Dungan, Kathleen M. ;
Guster, Tia ;
DeWalt, Darren A. ;
Buse, John B. .
CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (11) :2689-2695
[9]   Erythrocyte-Bound Apolipoprotein B in Relation to Atherosclerosis, Serum Lipids and ABO Blood Group [J].
Klop, Boudewijn ;
van de Geijn, Gert-Jan M. ;
Bovenberg, Sarah A. ;
van der Meulen, Noelle ;
Elte, Jan Willem F. ;
Birnie, Erwin ;
Njo, Tjin L. ;
Janssen, Hans W. ;
van Miltenburg, Addy ;
Jukema, J. Wouter ;
Cabezas, Manuel Castro .
PLOS ONE, 2013, 8 (09)
[10]   Daytime triglyceride variability in men and women with different levels of triglyceridemia [J].
Klop, Boudewijn ;
Cohn, Jeffrey S. ;
van Oostrom, Antonie J. H. H. M. ;
van Wijk, Jeroen P. H. ;
Birnie, Erwin ;
Cabezas, Manuel Castro .
CLINICA CHIMICA ACTA, 2011, 412 (23-24) :2183-2189